As previously reported, Barclays upgraded Novartis (NVS) to Equal Weight from Underweight with a CHF 120 price target as the firm transferred coverage of European large-cap pharma to a new analyst. The firm sees the company’s “fairly rich” pipeline as mostly well reflected in valuation or with competition, says the analyst, who also cites a “weak” operational outlook for 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Novartis upgraded to Equal Weight from Underweight at Barclays
- Trump Weekly: Furniture tariffs delayed, drugmakers hike prices
- Midday Fly By: Nvidia said to see strong H200 demand in China
- Pfizer (PFE) Tops List as Drugmakers Plan Price Hike on 350 Medications
- Trump Trade: 350 drugs to see price raises despite President’s pressure